These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 31865620)

  • 1. Measuring the impact of changing from standard half-life (SHL) to extended half-life (EHL) FVIII prophylaxis on health-related quality of life (HRQoL) in boys with moderate/severe haemophilia A: Lessons learned with the CHO-KLAT tool.
    Carcao M; Zunino L; Young NL; Dover S; Bouskill V; Hilliard P; Price VE; Blanchette VS
    Haemophilia; 2020 Jan; 26(1):73-78. PubMed ID: 31865620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics.
    Nummi V; Lehtinen AE; Iorio A; Szanto T; Lassila R
    Haemophilia; 2022 Nov; 28(6):e237-e244. PubMed ID: 35939628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
    Rakmanotham A; Moonla C; Sosothikul D
    Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Australian experience with switching to extended half-life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation.
    Brennan Y; Parikh S; McRae S; Tran H
    Haemophilia; 2020 May; 26(3):529-535. PubMed ID: 32243027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
    Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
    Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States.
    Aledort L; Milligan S; Watt M; Booth J
    J Manag Care Spec Pharm; 2020 Apr; 26(4):492-503. PubMed ID: 32223610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective study of health-related quality of life of boys with severe haemophilia A in China: comparing on-demand to prophylaxis treatment.
    Wu R; Sun J; Xiao J; Liu Y; Xue F; Wang H; Tang L; Zhao Y; Li K; Yang R; Hu Y; Luke KH; Poon MC; Blanchette VS; Usuba K; Young NL
    Haemophilia; 2017 May; 23(3):430-436. PubMed ID: 28345299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical application of extended half-life factor VIII in children with severe haemophilia A.
    Dettoraki A; Michalopoulou A; Mazarakis M; Saslis S; Stamati I; Kapsimali Z; Pergantou H
    Haemophilia; 2022 Jul; 28(4):619-624. PubMed ID: 35503081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efmoroctocog Alfa: A Review in Haemophilia A.
    Frampton JE
    Drugs; 2021 Nov; 81(17):2035-2046. PubMed ID: 34743314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor product utilization and health outcomes in patients with haemophilia A and B on extended half-life concentrates: A Canadian observational study of real-world outcomes.
    Sun HL; Yang M; Poon MC; Lee A; Robinson KS; Sholzberg M; Wu J; Iorio A; Blanchette V; Carcao M; Klaassen RJ; Jackson S
    Haemophilia; 2021 Sep; 27(5):751-759. PubMed ID: 34160870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validity of the Portuguese CHO-KLAT in Brazil.
    Villaça PR; Blanchette VS; Carneiro JD; Ozelo MC; Antunes S; Feldman BM; Abad A; Usuba K; Young NL
    Haemophilia; 2016 Nov; 22(6):894-897. PubMed ID: 27456858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Describing the quality of life of boys with haemophilia in China: Results of a multicentre study using the CHO-KLAT.
    Tang L; Xu W; Li CG; Hou F; Feng XQ; Wang H; Li XJ; Li WL; Liu JP; Sun LR; Wang SH; Jin J; Fang Q; Luke KH; Poon MC; Blanchette VS; Usuba K; Young NL; Wu R
    Haemophilia; 2018 Jan; 24(1):113-119. PubMed ID: 28922525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products.
    Tortella BJ; Alvir J; McDonald M; Spurden D; Fogarty PF; Chhabra A; Pleil AM
    J Manag Care Spec Pharm; 2018 Jul; 24(7):643-653. PubMed ID: 29363389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How well does the Canadian Haemophilia Outcomes-Kids' Life Assessment Tool (CHO-KLAT) measure the quality of life of boys with haemophilia?
    Young NL; Bradley CS; Wakefield CD; Barnard D; Blanchette VS; McCusker PJ
    Pediatr Blood Cancer; 2006 Sep; 47(3):305-11. PubMed ID: 16206209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single centre retrospective study of low dose prophylaxis with extended half-life factor IX for severe haemophilia B.
    Rampotas A; Desborough MJR; Raza-Burton S; Taylor S; Wilkinson A; Hall GW; Shapiro S; Curry N
    Haemophilia; 2020 Mar; 26(2):278-281. PubMed ID: 32083769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updating the Canadian Hemophilia Outcomes-Kids' Life Assessment Tool (CHO-KLAT) in the era of extended half-life clotting factor concentrates.
    Price VE; Dover S; Blanchette VS; Klaassen RJ; Belletrutti M; Bruce AAK; Chan AK; Wakefield C; Carcao M; Bouskill V; Young NL
    Res Pract Thromb Haemost; 2021 Mar; 5(3):403-411. PubMed ID: 33870026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis.
    Srichumpuang C; Rakmanotham A; Moonla C; Sosothikul D
    Orphanet J Rare Dis; 2024 Mar; 19(1):135. PubMed ID: 38532451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality of life in children with haemophilia in China: a 4-year follow-up prospective cohort study.
    Zhang H; Huang J; Kong X; Ma G; Fang Y
    Health Qual Life Outcomes; 2019 Feb; 17(1):28. PubMed ID: 30728017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of the Chinese version of the Canadian Haemophilia Outcomes-Kids' Life Assessment Tool (the CHO-KLAT).
    Wu R; Zhang J; Sun J; Zhou M; Wu JS; Li N; Li X; Luke KH; Poon MC; Blanchette VS; Young NL
    Haemophilia; 2014 Nov; 20(6):794-9. PubMed ID: 25273150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Converting factor and nonfactor usage into a single metric to facilitate benchmarking the resources consumed for haemophilia care across jurisdictions and over time.
    Stonebraker JS; O'Mahony B; Noone D; Iorio A
    Haemophilia; 2021 Sep; 27(5):e596-e608. PubMed ID: 34145693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.